Equities

Humanwell Healthcare Group Co Ltd

600079:SHH

Humanwell Healthcare Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)19.30
  • Today's Change-0.01 / -0.05%
  • Shares traded7.97m
  • 1 Year change-26.50%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Humanwell Healthcare (Group) Co., Ltd is a China-based company principally engaged in research and development, manufacture and distribution of medical and pharmaceutical products. The Company’s products are categorized into chemical drugs, chemical raw material medicines, traditional Chinese medicines, biological medicines and others. The Company also provides medical instruments. The Company distributes its products in both domestic market and to overseas markets.

  • Revenue in CNY (TTM)24.67bn
  • Net income in CNY1.96bn
  • Incorporated1993
  • Employees17.68k
  • Location
    Humanwell Healthcare Group Co LtdNo. 666 Gaoxin AvenueDonghu High-Tech DistrictWUHAN 430075ChinaCHN
  • Phone+86 2 787597232
  • Fax+86 2 787596393
  • Websitehttp://www.humanwell.com.cn
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
600079:SHH since
announced
Transaction
value
PAION AGAnnounced22 Dec 202322 Dec 2023Announced-24.84%--
Data delayed at least 15 minutes, as of May 31 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bluestar Adisseo Co13.53bn327.58m26.55bn2.73k81.051.76--1.960.12220.12225.045.630.62864.677.334,947,799.001.525.281.856.9423.8130.312.428.761.044.300.132521.81-9.262.92-95.82-43.752.74-19.09
Gan & Lee Pharmaceuticals2.61bn386.85m29.17bn4.48k72.252.64--11.170.67160.67164.5218.380.2340.892610.97582,412.303.478.303.718.8372.2985.3914.8326.447.74--0.000613.6552.311.78177.37-18.301.50--
Autobio Diagnostics Co Ltd4.50bn1.30bn30.07bn5.54k22.933.39--6.692.242.247.7415.110.40662.084.27811,768.3011.8112.5914.5015.7964.7661.6229.0426.962.81--0.103546.400.045718.154.2816.7017.0311.32
Humanwell Healthcare Group Co Ltd24.67bn1.96bn31.50bn17.68k15.991.80--1.281.211.2115.2510.730.68333.802.771,395,473.007.216.2013.2912.7245.0242.8210.559.841.2031.560.329318.879.795.65-14.07--8.25--
Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd8.15bn973.25m33.64bn4.62k27.803.87--4.131.271.2710.609.090.7443.123.241,765,208.008.718.9613.0612.8043.6840.8211.7010.671.62--0.138156.93-0.32665.2814.4911.93-4.3342.22
Hubei Jumpcan Pharmaceutical Co Ltd9.67bn2.99bn35.11bn5.23k11.682.46--3.633.263.2610.5415.510.55043.664.601,848,716.0017.0516.2322.5220.8879.7682.6430.9824.423.01--0.127541.767.326.0230.0410.83-14.701.11
Data as of May 31 2024. Currency figures normalised to Humanwell Healthcare Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

19.28%Per cent of shares held by top holders
HolderShares% Held
Harvest Fund Management Co., Ltd.as of 31 Dec 202350.59m3.47%
China Universal Asset Management Co., Ltd.as of 31 Dec 202344.75m3.07%
China Merchants Fund Management Co., Ltd.as of 30 Sep 202339.69m2.72%
Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 202330.89m2.12%
Penghua Fund Management Co., Ltd.as of 31 Dec 202323.73m1.63%
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 202322.17m1.52%
Zhong Ou Asset Management Co., Ltdas of 30 Sep 202319.03m1.31%
China Southern Asset Management Co., Ltd.as of 31 Dec 202318.84m1.29%
JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 202318.45m1.27%
GF Fund Management Co., Ltd.as of 30 Sep 202312.83m0.88%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.